IMPC phenotypes (gene matching)
C57BL/6NTac-Ftotm1(EGFP/cre/ERT2)Wtsi/WtsiH
| Status | Available to order |
| EMMA ID | EM:09765 |
| International strain name | C57BL/6NTac-Ftotm1(EGFP/cre/ERT2)Wtsi/WtsiH |
| Alternative name | CEPD0077_1_B10 |
| Strain type | |
| Allele/Transgene symbol | Ftotm1(EGFP/cre/ERT2)Wtsi |
| Gene/Transgene symbol | Fto |
Information from provider
| Provider | Wellcome Trust Sanger Institute |
| Provider affiliation | Wellcome Trust Sanger Institute |
| Genetic information | This mouse line originates from EUCOMM ES clone CEPD0077_1_B10. For further details on the construction of this clone see the page at the IMPC portal. Quality Control/Disclaimer: The structure of the targeted mutation is not fully verified. It is recommended that the recipient confirms the mutation structure by Southern blotting. The Cre expression pattern is expected to mirror that of the host gene, but this may not be fully described and/or may be modified in the targeted allele. Although characterisation of the Cre expression pattern is an objective of EUCOMMTools this is an ongoing process which may be incomplete. It is therefore recommended that the recipient verifies the Cre expression pattern. For the tm1(EGFP/Cre/ERT2) type allele, if the promoter-driven selection cassette is flanked with Rox sites, it may be removed using Dre recombinase. Please be aware that the strain description may be subject to change. For the most recent description please consult the information pages for the appropriate product details at the IMPC portal. |
| Phenotypic information | Potential phenotyping data in the IMPC portal |
| References | None available |
Information from EMMA
| Archiving centre | Mary Lyon Centre at MRC Harwell, Oxford, United Kingdom |
Disease and phenotype information
Orphanet associated rare diseases, based on orthologous gene matching
- Lethal polymalformative syndrome, Boissel type / Orphanet_210144
MGI phenotypes (gene matching)
- decreased bone mineral density / MGI
- decreased circulating LDL cholesterol level / MGI
- dermatitis / MGI
- decreased body length / MGI
- decreased body weight / MGI
- hyperactivity / MGI
- hypoactivity / MGI
- abnormal eating behavior / MGI
- polyphagia / MGI
- increased circulating triglyceride level / MGI
- increased circulating HDL cholesterol level / MGI
- postnatal growth retardation / MGI
- increased circulating glucagon level / MGI
- decreased circulating insulin level / MGI
- decreased circulating alanine transaminase level / MGI
- increased lean body mass / MGI
- decreased lean body mass / MGI
- decreased circulating iron level / MGI
- decreased circulating insulin-like growth factor I level / MGI
- increased energy expenditure / MGI
- cachexia / MGI
- increased circulating cholesterol level / MGI
- abnormal metabolism / MGI
- abnormal oxygen consumption / MGI
- increased oxygen consumption / MGI
- improved glucose tolerance / MGI
- homeostasis/metabolism phenotype / MGI
- growth/size/body region phenotype / MGI
- abnormal circulating hormone level / MGI
- decreased percent body fat/body weight / MGI
- increased circulating glucose level / MGI
- decreased lactate dehydrogenase level / MGI
- decreased circulating aspartate transaminase level / MGI
- increased susceptibility to diet-induced obesity / MGI
- decreased susceptibility to diet-induced obesity / MGI
- increased circulating adrenaline level / MGI
- decreased circulating leptin level / MGI
- increased circulating leptin level / MGI
- abnormal carbon dioxide production / MGI
- increased carbon dioxide production / MGI
- decreased carbon dioxide production / MGI
- increased basal metabolism / MGI
- decreased white fat cell size / MGI
- decreased gonadal fat pad weight / MGI
- increased total body fat amount / MGI
- decreased total body fat amount / MGI
- increased respiratory quotient / MGI
- decreased respiratory quotient / MGI
- postnatal lethality, incomplete penetrance / MGI
- preweaning lethality, incomplete penetrance / MGI
- abnormal urine catecholamine level / MGI
- increased food intake / MGI